JP2017514471A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514471A5 JP2017514471A5 JP2016563936A JP2016563936A JP2017514471A5 JP 2017514471 A5 JP2017514471 A5 JP 2017514471A5 JP 2016563936 A JP2016563936 A JP 2016563936A JP 2016563936 A JP2016563936 A JP 2016563936A JP 2017514471 A5 JP2017514471 A5 JP 2017514471A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- cell
- seq
- antigen
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 claims description 73
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 67
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 14
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 13
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 13
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- -1 GP240 Proteins 0.000 claims description 10
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 7
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 6
- 102000008579 Transposases Human genes 0.000 claims description 6
- 108010020764 Transposases Proteins 0.000 claims description 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 5
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102000001301 EGF receptor Human genes 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims description 3
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 3
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 3
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 3
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 3
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 3
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims description 3
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 3
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 3
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 3
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 3
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 3
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 3
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 3
- 241000192019 Human endogenous retrovirus K Species 0.000 claims description 3
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 3
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 3
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 3
- 102000003735 Mesothelin Human genes 0.000 claims description 3
- 108090000015 Mesothelin Proteins 0.000 claims description 3
- 102100034256 Mucin-1 Human genes 0.000 claims description 3
- 108010008707 Mucin-1 Proteins 0.000 claims description 3
- 102100023123 Mucin-16 Human genes 0.000 claims description 3
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 claims description 3
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 3
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 claims description 3
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims description 3
- 102100035721 Syndecan-1 Human genes 0.000 claims description 3
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 3
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 3
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 3
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 229950010203 nimotuzumab Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 240000007019 Oxalis corniculata Species 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 69
- 210000001744 T-lymphocyte Anatomy 0.000 description 37
- 230000009261 transgenic effect Effects 0.000 description 16
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- 238000012258 culturing Methods 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983298P | 2014-04-23 | 2014-04-23 | |
| US201461983103P | 2014-04-23 | 2014-04-23 | |
| US61/983,298 | 2014-04-23 | ||
| US61/983,103 | 2014-04-23 | ||
| PCT/US2015/027277 WO2015164594A1 (en) | 2014-04-23 | 2015-04-23 | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020023077A Division JP2020072755A (ja) | 2014-04-23 | 2020-02-14 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017514471A JP2017514471A (ja) | 2017-06-08 |
| JP2017514471A5 true JP2017514471A5 (enExample) | 2018-05-24 |
Family
ID=53055122
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563936A Withdrawn JP2017514471A (ja) | 2014-04-23 | 2015-04-23 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| JP2020023077A Pending JP2020072755A (ja) | 2014-04-23 | 2020-02-14 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| JP2022074648A Pending JP2022093564A (ja) | 2014-04-23 | 2022-04-28 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| JP2023130951A Pending JP2023138812A (ja) | 2014-04-23 | 2023-08-10 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020023077A Pending JP2020072755A (ja) | 2014-04-23 | 2020-02-14 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| JP2022074648A Pending JP2022093564A (ja) | 2014-04-23 | 2022-04-28 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| JP2023130951A Pending JP2023138812A (ja) | 2014-04-23 | 2023-08-10 | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20170158749A1 (enExample) |
| EP (1) | EP3134437A1 (enExample) |
| JP (4) | JP2017514471A (enExample) |
| KR (1) | KR20160145802A (enExample) |
| CN (1) | CN106459924A (enExample) |
| AU (1) | AU2015249655B2 (enExample) |
| CA (1) | CA2945388A1 (enExample) |
| WO (1) | WO2015164594A1 (enExample) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| AU2014265487B2 (en) | 2013-05-14 | 2020-10-22 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (CAR) T-cells |
| US9701758B2 (en) | 2013-05-24 | 2017-07-11 | Board Of Regents, The University Of Texas System | Anti-CD19 scFv (FMC63) polypeptide |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| ES2764471T3 (es) | 2014-02-14 | 2020-06-03 | Univ Texas | Receptores de antígeno quimérico y procedimientos de fabricación |
| EP4219687B1 (en) | 2014-04-23 | 2024-08-14 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| FR3026744B1 (fr) | 2014-10-06 | 2024-04-19 | Hopitaux Paris Assist Publique | Methode de generation de progeniteurs de cellules t |
| CA2964783C (en) | 2014-11-05 | 2024-01-23 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| EP3240805B1 (en) | 2014-12-15 | 2024-11-27 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| CA2976126A1 (en) | 2015-02-24 | 2016-09-01 | Board Of Regents, The University Of Texas System | Selection methods for genetically-modified t cells |
| RU2020127887A (ru) | 2015-03-11 | 2020-10-02 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Полипептиды транспозазы и их применение |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11420136B2 (en) | 2016-10-19 | 2022-08-23 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| CA2994412A1 (en) * | 2015-07-31 | 2017-02-09 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting cd56 and uses thereof |
| GB2595063B (en) | 2015-07-31 | 2022-03-09 | Univ Minnesota | Modified cells and methods of therapy |
| JP7020687B2 (ja) | 2015-09-15 | 2022-02-16 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｔ細胞受容体（ｔｃｒ）結合抗体及びその使用 |
| WO2017075147A1 (en) | 2015-10-27 | 2017-05-04 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor molecules and uses thereof |
| ES2909973T3 (es) * | 2015-11-04 | 2022-05-10 | Hope City | Receptores quiméricos para el antígeno que se dirigen a HER2 |
| AU2016352912A1 (en) * | 2015-11-09 | 2018-05-31 | Aperisys, Inc. | Modified immune cells and uses thereof |
| WO2017132535A1 (en) | 2016-01-28 | 2017-08-03 | The Regents Of The University Of California | Methods for selectively expanding and enriching cells transduced with chimeric antigen receptors and treating hiv infection |
| ES2879700T3 (es) * | 2016-02-05 | 2021-11-22 | Hope City | Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| US20190119758A1 (en) * | 2016-04-22 | 2019-04-25 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| CN109311991B (zh) | 2016-06-06 | 2022-08-30 | 希望之城 | Baff-r靶向嵌合抗原受体修饰的t细胞及其用途 |
| US20200208111A1 (en) * | 2016-06-09 | 2020-07-02 | Branden S. Moriarity | Genome-edited nk cell and methods of making and using |
| CN107523547A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抑制性抗体的car‑t细胞及其用途 |
| US11583555B2 (en) | 2016-06-24 | 2023-02-21 | University of Pittsburgh—of the Commonwealth System of Higher Education | Genetic re-engineering of immune cells to improve metabolic fitness for immunotherapy |
| CN107663240B (zh) | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| AU2017319151B2 (en) | 2016-08-30 | 2024-01-11 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| US20190336533A1 (en) | 2016-12-28 | 2019-11-07 | Green Cross Lab Cell Corporation | Chimeric antigen receptor and natural killer cells expressing same |
| IL268641B2 (en) | 2017-02-13 | 2024-10-01 | Assist Publique Hopitaux Paris Aphp | Method for generating t cells progenitors |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| CN107099603A (zh) * | 2017-05-31 | 2017-08-29 | 成都克里斯博生物科技有限公司 | 肿瘤免疫t细胞检测试剂盒和检测方法 |
| GB201709203D0 (en) * | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| JP7210534B2 (ja) * | 2017-07-12 | 2023-01-23 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・リーランド・スタンフォード・ジュニア・ユニバーシティ | Ｈ３ｋ２７ｍ変異を有するがんの処置のための組成物および方法 |
| EP3658163A4 (en) * | 2017-07-25 | 2021-08-04 | Board Of Regents, The University Of Texas System | NOVEL CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF |
| TWI676483B (zh) * | 2017-08-06 | 2019-11-11 | 強普生技股份有限公司 | 醫藥套組及其用途 |
| CN107287165A (zh) * | 2017-08-23 | 2017-10-24 | 湖南开启时代生物科技有限责任公司 | 一种car‑t细胞的制备方法 |
| WO2019047932A1 (zh) * | 2017-09-08 | 2019-03-14 | 科济生物医药（上海）有限公司 | 基因工程化的t细胞及应用 |
| KR20250024096A (ko) * | 2017-09-29 | 2025-02-18 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 돌연변이된 p53을 인식하는 t 세포 수용체 |
| CN107488738B (zh) * | 2017-10-12 | 2020-04-28 | 中国医学科学院肿瘤医院 | 一种预测乳腺癌对曲妥珠单抗联合化疗治疗敏感性的生物标志物 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CA3082328A1 (en) | 2017-11-14 | 2019-05-23 | Green Cross Lab Cell Corporation | Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US20200209240A1 (en) * | 2017-11-20 | 2020-07-02 | Julius-Maximilians-Universität Würzburg | Cd19cart cells eliminate myeloma cells that express very low levels of cd19 |
| CU24558B1 (es) * | 2017-11-28 | 2021-12-08 | Ct Inmunologia Molecular | Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
| CN108070033A (zh) * | 2017-12-12 | 2018-05-25 | 武汉波睿达生物科技有限公司 | 一种3bnc-car分子的构建及其在杀灭hiv-1感染细胞中的应用 |
| BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
| CN118949017A (zh) | 2017-12-15 | 2024-11-15 | 小利兰·斯坦福大学托管委员会 | 抑制t细胞衰竭的组合物和方法 |
| EP3728330A4 (en) * | 2017-12-23 | 2021-12-08 | Uwell Biopharma Inc. | PHARMACEUTICAL COMPOSITION OF CHEMICAL RECEPTOR AND ASSOCIATED PROCESS |
| CA3086832A1 (en) | 2018-01-03 | 2019-07-11 | Qu Biologics Inc. | Innate targeting of adoptive cellular therapies |
| US11965191B2 (en) | 2018-01-18 | 2024-04-23 | California Institute Of Technology | Programmable protein circuits in living cells |
| AU2019209432B2 (en) | 2018-01-22 | 2026-01-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| US11696943B2 (en) | 2018-01-23 | 2023-07-11 | Vanderbilt University | Self-antigen specific T-cells as vaccines for augmenting engraftment and stability of autologous transfer |
| AU2019218729B2 (en) | 2018-02-06 | 2025-12-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| RU2020132924A (ru) * | 2018-03-08 | 2022-04-11 | Рубиус Терапьютикс, Инк. | Терапевтические клеточные системы и способы лечения рака и инфекционных заболеваний |
| WO2019204664A2 (en) * | 2018-04-19 | 2019-10-24 | Apdn (B.V.I), Inc. | Engineered lymphocyte compositions, methods and systems |
| CA3099364A1 (en) | 2018-05-11 | 2019-11-14 | Crispr Therapeutics Ag | Methods and compositions for treating cancer comprising engineered t cells comprising modified chimeric antigen receptors |
| JP7617839B2 (ja) * | 2018-07-09 | 2025-01-20 | プレシゲン，インコーポレイテッド | 融合構築物およびその使用法 |
| SG11202100616VA (en) * | 2018-08-07 | 2021-03-30 | Purdue Research Foundation | Rejuvenation of car t cell |
| CN110862967A (zh) * | 2018-08-27 | 2020-03-06 | 天津天锐生物科技有限公司 | 一种不依赖细胞因子培养的自然杀伤细胞系silk-nk |
| WO2020047320A1 (en) | 2018-08-31 | 2020-03-05 | California Institute Of Technology | Synthetic protein circuits detecting signal transducer activity |
| KR20210056377A (ko) * | 2018-09-07 | 2021-05-18 | 소티오, 엘엘씨 | 세포내 락테이트 농도를 조절하는 트랜스 대사 분자와 조합된 키메라 수용체 폴리펩타이드 및 이의 치료 용도 |
| US20210386781A1 (en) * | 2018-10-05 | 2021-12-16 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3908653A4 (en) | 2019-01-10 | 2022-11-02 | California Institute of Technology | A synthetic system for tunable thresholding of protein signals |
| US20220088190A1 (en) * | 2019-01-25 | 2022-03-24 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Targeting Mutant RAS |
| US12404347B2 (en) | 2019-02-07 | 2025-09-02 | Board Of Regents, The University Of Texas System | Glucuronoxylomannan (GXM) receptor chimeric antigen receptors and use thereof |
| CA3129100A1 (en) * | 2019-02-08 | 2020-08-13 | Biontech Cell & Gene Therapies Gmbh | Treatment involving car-engineered t cells and cytokines |
| KR20210129105A (ko) | 2019-02-15 | 2021-10-27 | 에디타스 메디신, 인코포레이티드 | 면역치료법을 위한 변형된 자연 살해(nk) 세포 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| AU2020267057A1 (en) | 2019-04-30 | 2021-11-18 | Crispr Therapeutics Ag | Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19 |
| MX2021015125A (es) * | 2019-06-07 | 2022-04-06 | Juno Therapeutics Inc | Cultivo automatizado de celulas t. |
| WO2020247837A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| WO2021092333A1 (en) * | 2019-11-06 | 2021-05-14 | Baylor College Of Medicine | Method for producing cytotoxic effector memory t cells for t-cell treatment of cancer |
| CN115003386A (zh) * | 2019-11-27 | 2022-09-02 | 宾夕法尼亚大学董事会 | 产生抗cd3 scfv和细胞因子的人工抗原呈递细胞 |
| AU2020401315B2 (en) * | 2019-12-11 | 2023-11-09 | A2 Biotherapeutics, Inc. | LILRB1-based chimeric antigen receptor |
| WO2021170666A1 (en) * | 2020-02-25 | 2021-09-02 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| CN111253493B (zh) * | 2020-03-05 | 2021-03-23 | 武汉科技大学 | 一种靶向hiv病毒囊膜双位点的嵌合抗原受体及其表达载体和应用 |
| US12264190B2 (en) * | 2020-04-24 | 2025-04-01 | Astrazeneca Ab | Compositions and methods of treating cancer with chimeric antigen receptors |
| EP4178680A4 (en) | 2020-07-10 | 2024-07-31 | Precigen, Inc. | FUSION CONSTRUCTS AND THEIR METHODS OF USE |
| KR102605723B1 (ko) * | 2020-11-11 | 2023-11-24 | 한국과학기술원 | 키메라 항원 수용체를 위한 타깃 항원 발굴 방법 및 분석 장치 |
| CN114716548B (zh) * | 2021-01-05 | 2024-11-05 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
| US20240327889A1 (en) * | 2021-04-05 | 2024-10-03 | Victor TETS | Regulation of cells and organisms |
| US20250073264A1 (en) * | 2021-04-08 | 2025-03-06 | Artiva Biotherapeutics, Inc. | Chimeric antigen receptor comprising an anti-her2 antibody or antigen-binding fragment thereof and natural killer cells comprising the same |
| US20240293543A1 (en) | 2021-06-23 | 2024-09-05 | Editas Medicine, Inc. | Engineered cells for therapy |
| EP4130028A1 (en) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Engineered tcr complex and methods of using same |
| JP2024536647A (ja) | 2021-08-03 | 2024-10-07 | ジェニシティー リミテッド | 操作されたｔｃｒ複合体及びそれを使用する方法 |
| WO2023021494A1 (en) * | 2021-08-20 | 2023-02-23 | Rudd Christopher E | Compositions and methods for anti-virus chimeric antigen receptor |
| EP4504799A1 (en) | 2022-04-08 | 2025-02-12 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| MX2024008227A (es) | 2022-04-08 | 2024-07-19 | Fate Therapeutics Inc | Celulas que tienen cadena principal dirigida a tumores solidos y uso de estas. |
| CN115873803B (zh) * | 2022-11-28 | 2025-06-17 | 上海恩凯细胞技术有限公司 | 提高nk细胞存活和抗肿瘤活性的方法及应用 |
| WO2025106453A1 (en) * | 2023-11-13 | 2025-05-22 | California Institute Of Technology | Synpoptosis circuits for programmable cell death control |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| CA2214649C (en) | 1995-03-08 | 2007-06-12 | Zeling Cai | Antigen presenting system and methods for activation of t-cells |
| DK0969865T3 (da) | 1996-05-23 | 2007-03-19 | Scripps Research Inst | Systemer til præsentation af MHC-antigener af klasse II og fremgangsmåder til aktivering af CD4+-T-celller |
| EP0973928B1 (en) | 1997-03-11 | 2010-05-05 | Regents Of The University Of Minnesota | Dna-based transposon system for the introduction of nucleic acid into dna of a cell |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| US7993638B2 (en) | 2006-03-01 | 2011-08-09 | Janssen Pharmaceutica Nv | Cancer treatment combining lymphodepleting agent with CTLs and cytokines |
| US8124408B2 (en) | 2006-10-04 | 2012-02-28 | Janssen Pharmaceutica N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| HRP20211788T1 (hr) * | 2008-08-26 | 2022-02-18 | City Of Hope | Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica |
| EA201391059A1 (ru) * | 2011-01-18 | 2014-05-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Композиции для лечения рака и способы их применения |
| CA3115406A1 (en) | 2011-01-24 | 2012-08-02 | National Research Council Of Canada | Antibodies selective for cells presenting egfr at high density |
| CN107164330A (zh) * | 2011-04-08 | 2017-09-15 | 贝勒医学院 | 使用嵌合细胞因子受体逆转肿瘤微环境的影响 |
| WO2013123061A1 (en) * | 2012-02-13 | 2013-08-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US9701758B2 (en) | 2013-05-24 | 2017-07-11 | Board Of Regents, The University Of Texas System | Anti-CD19 scFv (FMC63) polypeptide |
| KR20160079854A (ko) * | 2013-10-31 | 2016-07-06 | 프레드 헛친슨 켄서 리서치 센터 | 변형된 조혈 줄기/선조 및 비-t 효과기 세포 및 이의 용도 |
-
2015
- 2015-04-23 US US15/305,996 patent/US20170158749A1/en not_active Abandoned
- 2015-04-23 CN CN201580026693.4A patent/CN106459924A/zh active Pending
- 2015-04-23 AU AU2015249655A patent/AU2015249655B2/en not_active Ceased
- 2015-04-23 CA CA2945388A patent/CA2945388A1/en active Pending
- 2015-04-23 EP EP15721090.7A patent/EP3134437A1/en active Pending
- 2015-04-23 WO PCT/US2015/027277 patent/WO2015164594A1/en not_active Ceased
- 2015-04-23 KR KR1020167032607A patent/KR20160145802A/ko not_active Ceased
- 2015-04-23 JP JP2016563936A patent/JP2017514471A/ja not_active Withdrawn
-
2019
- 2019-10-14 US US16/600,806 patent/US20200102366A1/en not_active Abandoned
-
2020
- 2020-02-14 JP JP2020023077A patent/JP2020072755A/ja active Pending
-
2022
- 2022-04-28 JP JP2022074648A patent/JP2022093564A/ja active Pending
-
2023
- 2023-01-11 US US18/153,025 patent/US20230312675A1/en active Pending
- 2023-08-10 JP JP2023130951A patent/JP2023138812A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514471A5 (enExample) | ||
| CN113286879B (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| Patel et al. | From concept to cure: The evolution of CAR-T cell therapy | |
| Palladini et al. | Virus-like particle display of HER2 induces potent anti-cancer responses | |
| ES2989596T3 (es) | Receptores que proporcionan coestimulación dirigida para terapia celular adoptiva | |
| AU2016306209B2 (en) | Bispecific CAR T-cells for solid tumor targeting | |
| JP7584414B2 (ja) | 複数の免疫細胞タイプの同時増殖のための方法、関連する組成物および癌免疫療法におけるそれらの使用 | |
| AU2014225788B2 (en) | Engager cells for immunotherapy | |
| Kang et al. | Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects | |
| US20210338729A1 (en) | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF | |
| HK1254962A1 (zh) | 具有改进特异性的修饰的t淋巴细胞 | |
| JP2016525881A5 (enExample) | ||
| CN110573177A (zh) | 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car) | |
| CN111163758A (zh) | 具有记忆功能的t细胞或b细胞的增强剂、恶性肿瘤复发抑制剂、以及对t细胞或b细胞诱导记忆功能的诱导剂 | |
| Han et al. | Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors | |
| Larson et al. | Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy | |
| JP2025508050A (ja) | Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞 | |
| Fenton et al. | Cellular cancer immunotherapy development and manufacturing in the clinic | |
| US11034773B2 (en) | Methods and materials for treating cancer | |
| CN114599400A (zh) | 用于治疗癌症的医药、组合医药、医药组合物、免疫应答细胞、核酸递送介质和制品 | |
| Olivera et al. | Regional and intratumoral adoptive T-cell therapy | |
| TWI817350B (zh) | 與Globo系列抗原結合之嵌合抗原受體及其用途 | |
| Yoon et al. | Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR) | |
| Chen et al. | A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells | |
| JP2020535832A (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |